Paper
0
Teclistamab in Relapsed or Refractory Multiple Myeloma
Authors
Philippe Moreau,Alfred Garfall
Niels Donk,Hareth Nahi,Jesús Miguel,Albert Oriol,Ajay Nooka,Thomas Martin,Laura Rosiñol,Ajai Chari,Lionel Karlin,Lotfi Benboubker,María‐Victoria Mateos,Nizar Bahlis,Rakesh Popat,Britta Besemer,Joaquín Martínez‐López,Surbhi Sidana,Michel Attal,Lixia Pei,Danielle Trancucci,Raluca Verona,Suzette Girgis,Shun Lin,Yunsi Olyslager,Mindy Jaffe,Clarissa Uhlar,Tara Stephenson,Rian Rampelbergh,Arnob Banerjee,Jenna Goldberg,Rachel Kobos,Amrita Krishnan
+31 authors
,Saad UsmaniPublished
Jun 5, 2022
Show more
Save
Tip0
TipSave
Abstract
Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.